<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592640</url>
  </required_header>
  <id_info>
    <org_study_id>Stem cell</org_study_id>
    <nct_id>NCT04592640</nct_id>
  </id_info>
  <brief_title>Stem Cells for Uremic Calciphylaxis Patients</brief_title>
  <official_title>Effects of Human Amniotic Mesenchymal Stem Cells (hAMSCs) on Wound Healing in Uremic Calciphylaxis Patients: an Open Label Single Arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ningning Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment for Uremic Calciphylaxis Patients with Human Amniotic Mesenchymal Stem Cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calciphylaxis is a rare, devastating disorder causing excruciatingly painful ischemic skin&#xD;
      lesions. Sepsis due to the infection of ulcerated wounds is a common cause of death. To date,&#xD;
      practical therapies typically include wound care, pain management, anti-infection and&#xD;
      aggressive treatment of predisposing conditions. Drugs such as sodium thiosulfate,&#xD;
      bisphosphonate, and cinacalcet are also suggested. However, it's still a lethal disease with&#xD;
      1-year mortality up to 80% for dialysis patients. Here the investigators plan to treat uremic&#xD;
      calciphylaxis patients with human amniotic mesenchymal stem cells (hAMSCs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">September 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Healing</measure>
    <time_frame>Up to 1 year.</time_frame>
    <description>The Bates-Jensen Wound Assessment (BWAT) is a standardized tool for quantitative assessment of wound healing that includes the 13 items listed below: (1)Size; (2)Depth; (3)Edges; (4)Undermining or pockets; (5)Necrotic tissue type; (6)Necrotic tissue amount; (7)Exudate type; (8)Exudate amount; (9)Surrounding skin color; (10)Peripheral tissue edema; (11)Peripheral tissue induration; (12)Granulation tissue; (13)Epithelialization.&#xD;
Each item was rated on a scale of 1 (best) to 5 (worst). The BWAT total score is the sum of the individual items with a possible range of 13 (best) to 65 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound Pain</measure>
    <time_frame>Up to 1 year.</time_frame>
    <description>Assessed by pain visual analog scale (VAS). VAS Score is a horizontal line, 100 mm in length, anchored by word descriptors at each end. The subject marked the point on the line that represented his/her perception of his/her current pain status. VAS Score was determined by measuring in millimeters from the left hand end of the line (no pain) to the point that the subject marked. VAS Score range 0 (best) to 100 (Worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured Quality of Life</measure>
    <time_frame>Up to 1 year.</time_frame>
    <description>The wound-quality of life(QoL) questionnaire measures the disease-specific, health related QoL of patients with chronic wounds. It consists of 17 items on impairments that are assessed in retrospect to the preceding 7 days and rated on a 0 (best) to 4 (worse) scale with possible responses from &quot;not at all&quot; to &quot;very much&quot;. The total score is the average of the 17 responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Infection</measure>
    <time_frame>Up to 1 year.</time_frame>
    <description>Assessed by serum hypersensitive C-reactive protein level(hCRP, mg/L). Increased serum hCRP levels above normal ranges indicate infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival State</measure>
    <time_frame>From date of treatment until the date of die, assessed up to 1 year.</time_frame>
    <description>Survival time from the hAMSCs treatment started(momths)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Calciphylaxis</condition>
  <condition>Calcific Uremic Arteriolopathy</condition>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>Uremic Calciphylaxis Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human amniotic mesenchymal stem cells (hAMSCs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Human amniotic mesenchymal stem cells</intervention_name>
    <description>Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).&#xD;
Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).</description>
    <arm_group_label>Uremic Calciphylaxis Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-60 years old.&#xD;
&#xD;
          2. Patients with chronic kidney disease who did not or had regular dialysis (hemodialysis&#xD;
             or peritoneal dialysis).&#xD;
&#xD;
          3. Clinical diagnosis of calciphylaxis.&#xD;
&#xD;
          4. All subjects signed informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients who refuse to sign informed consent.&#xD;
&#xD;
          2. Patients with malignant tumor or serious mental disease, cardiovascular disease,&#xD;
             shock, abnormal liver function and secondary kidney disease.&#xD;
&#xD;
          3. Pregnant or lactating women of childbearing age.&#xD;
&#xD;
          4. Participation in another clinical trial with an experimental drug within 90 days prior&#xD;
             the inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ningning Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiayin Liu, Professor</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lianju Qin</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nejm.org/doi/full/10.1056/NEJMra1505292</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/30304522</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/27712637</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/31681640</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/28603903</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/30775620</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/24075020/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018 May 3;378(18):1704-1714. doi: 10.1056/NEJMra1505292. Review.</citation>
    <PMID>29719190</PMID>
  </reference>
  <reference>
    <citation>Seethapathy H, Brandenburg VM, Sinha S, El-Azhary RA, Nigwekar SU. Review: update on the management of calciphylaxis. QJM. 2019 Jan 1;112(1):29-34. doi: 10.1093/qjmed/hcy234. Review.</citation>
    <PMID>30304522</PMID>
  </reference>
  <reference>
    <citation>McCarthy JT, El-Azhary RA, Patzelt MT, Weaver AL, Albright RC, Bridges AD, Claus PL, Davis MD, Dillon JJ, El-Zoghby ZM, Hickson LJ, Kumar R, McBane RD, McCarthy-Fruin KA, McEvoy MT, Pittelkow MR, Wetter DA, Williams AW. Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis. Mayo Clin Proc. 2016 Oct;91(10):1384-1394. doi: 10.1016/j.mayocp.2016.06.025.</citation>
    <PMID>27712637</PMID>
  </reference>
  <reference>
    <citation>Baby D, Upadhyay M, Joseph MD, Asopa SJ, Choudhury BK, Rajguru JP, Gupta S. Calciphylaxis and its diagnosis: A review. J Family Med Prim Care. 2019 Sep 30;8(9):2763-2767. doi: 10.4103/jfmpc.jfmpc_588_19. eCollection 2019 Sep. Review.</citation>
    <PMID>31681640</PMID>
  </reference>
  <reference>
    <citation>Peng T, Zhuo L, Wang Y, Jun M, Li G, Wang L, Hong D. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology (Carlton). 2018 Jul;23(7):669-675. doi: 10.1111/nep.13081. Review.</citation>
    <PMID>28603903</PMID>
  </reference>
  <reference>
    <citation>Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis. Kidney Int Rep. 2018 Oct 9;4(2):231-244. doi: 10.1016/j.ekir.2018.10.002. eCollection 2019 Feb.</citation>
    <PMID>30775620</PMID>
  </reference>
  <reference>
    <citation>Torregrosa JV, Sánchez-Escuredo A, Barros X, Blasco M, Campistol JM. Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates. Clin Nephrol. 2015 Apr;83(4):231-4. doi: 10.5414/CN107923.</citation>
    <PMID>24075020</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Ningning Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Diseases</keyword>
  <keyword>Calciphylaxis</keyword>
  <keyword>Calcific Uremic Arteriolopathy</keyword>
  <keyword>Human Amniotic Mesenchymal Stem Cells</keyword>
  <keyword>Rare disease (ORPHA280062)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Calciphylaxis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

